Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models
- 1 March 2004
- journal article
- review article
- Published by Elsevier in Clinics in Perinatology
- Vol. 31 (1), 129-142
- https://doi.org/10.1016/j.clp.2004.03.004
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Erythropoietin Is a Paracrine Mediator of Ischemic Tolerance in the Brain: Evidence from anIn VitroModelJournal of Neuroscience, 2002
- THE USE OF ERYTHROPOIETIN IN NEONATESClinics in Perinatology, 2000
- Physiology and function of the erythropoietin receptorCurrent Opinion in Hematology, 1998
- Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasisJournal of Laboratory and Clinical Medicine, 1998
- The Erythropoietin Receptor and Signal TransductionThe Oncologist, 1996
- Assignment of the Hypoxia-Inducible Factor 1α Gene to a Region of Conserved Synteny on Mouse Chromosome 12 and Human Chromosome 14qGenomics, 1996
- Activation and inhibition of erythropoietin receptor function: role of receptor dimerization.Molecular and Cellular Biology, 1994
- Homodimerization and constitutive activation of the erythropoietin receptor.Proceedings of the National Academy of Sciences, 1992
- Erythropoietin: Biology and Clinical ApplicationsJournal of Pediatric Hematology/Oncology, 1991
- A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chainBiochemical and Biophysical Research Communications, 1989